Norfloxacin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Norfloxacin: From Bacterial Infections to Septicemic Plague
Note on Candidate Selection
This evidence pack contains 10 TxGNN-predicted indications for norfloxacin, all clustered at similar TxGNN scores (99.4–99.7%). Rank 1 by raw score ("hyperamylasemia") has zero clinical, literature, or mechanistic support — the pack itself annotates it as "無機轉關聯，無臨床或文獻證據支持" (no mechanistic link, no evidence). The same is true for ranks 2, 3, 4, 6, 7, 8, 9. Rank 5 ("punctate epithelial keratoconjunctivitis") has literature, but the pack flags it as a likely false positive — the cited cases are microsporidial (parasitic), not bacterial, and norfloxacin's antibacterial mechanism does not apply.
Of the 10 candidates, only rank 10 (septicemic plague) carries a biologically coherent rationale and a higher evidence tier (L3, decision stage S2 "Research Question"). This report focuses on that candidate rather than blindly following score rank, and lists the other 9 as screened-out in the appendix below.
One-Sentence Summary
Norfloxacin is a fluoroquinolone-class antibacterial agent, historically used to treat bacterial infections (e.g., urinary tract infections) via DNA gyrase inhibition. Among the TxGNN predictions in this pack, the most credible new-indication candidate is Septicemic Plague, based on class-effect reasoning with CDC/WHO-recommended fluoroquinolones (ciprofloxacin, levofloxacin) — but it is supported only by 2 historical animal/in-vitro publications and no clinical trials or norfloxacin-specific plague data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack — no NZ/TW license records available (norfloxacin is a well-established fluoroquinolone antibacterial; specific approved wording pending TFDA package insert retrieval, DG001) |
| Predicted New Indication | Septicemic Plague |
| TxGNN Prediction Score | 99.37% |
| Evidence Level | L3 |
| New Zealand Market Status | ✗ Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (data gap DG002, High severity). Based on known pharmacology, norfloxacin is a fluoroquinolone-class antibacterial, and this class's efficacy against susceptible Gram-negative bacteria — including Yersinia pestis, the causative agent of plague — is well established for other members of the class (ciprofloxacin, levofloxacin, both CDC/WHO-recommended for plague treatment and post-exposure prophylaxis).
The mechanistic thread connecting norfloxacin's original antibacterial use to septicemic plague is a class-effect argument: all fluoroquinolones inhibit bacterial DNA gyrase/topoisomerase IV, and this mechanism is pathogen-agnostic within susceptible Gram-negative species. Since Y. pestis is susceptible to fluoroquinolones as a class, norfloxacin's inclusion is mechanistically plausible even without drug-specific trial data.
However, this rationale is indirect. The two supporting publications (PMID 10987101, 11057367) are animal/in-vitro studies from 2000, in Russian-language literature, and neither directly tests norfloxacin against Y. pestis in a clinical or robust preclinical model — one focuses on vaccine-antibiotic interaction in mice, the other on a different pathogen (Vibrio cholerae) entirely. This is class-level, not drug-level, evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10987101 | 2000 | Animal Study | Antibiotiki i khimioterapiia | Compared combined emergency (fluoroquinolone) + specific (EV vaccine) prophylaxis vs. sequential use in mice; norfloxacin's effect on post-vaccination immunity was noted as lower than ciprofloxacin/ofloxacin/pefloxacin |
| 11057367 | 2000 | In Vitro Study | Antibiotiki i khimioterapiia | Examined fluoroquinolone resistance mutants in Vibrio cholerae (not Yersinia pestis); indirect class-effect relevance only |
New Zealand Market Information
No marketing authorizations are on record. market_status = 未上市 (Not Marketed), total_licenses = 0.
Safety Considerations
Please refer to the package insert for safety information. (Note: TFDA/Medsafe package insert retrieval is a Blocking data gap (DG001) — this prevents entry into the S1 safety review stage.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for septicemic plague is limited to L3 class-effect reasoning drawn from two 25-year-old animal/in-vitro studies, with no norfloxacin-specific clinical or preclinical plague data. Safety review cannot proceed because the TFDA/Medsafe package insert data (DG001) is a blocking gap, and norfloxacin is not marketed in the target jurisdiction.
To proceed, the following is needed:
- Resolve DG001 (TFDA/Medsafe package insert — warnings/contraindications) to unblock S1 safety review
- Resolve DG002 (confirmed MOA from DrugBank) to strengthen the mechanistic rationale
- Norfloxacin-specific in vitro/in vivo efficacy data against Yersinia pestis
- Reassess whether the other 9 TxGNN-predicted indications in this pack merit any further screening, given current evidence gaps
Appendix: Other Screened Candidates (Not Selected)
| Rank | Disease | TxGNN Score | Evidence Level | Reason Excluded | |------|---------|------|------|------| | 1 | Hyperamylasemia | 99.70% | L5 | No mechanistic link, no clinical/literature evidence | | 2 | Polyclonal hyperviscosity syndrome | 99.70% | L5 | No mechanistic link, no evidence | | 3 | Congenital analbuminemia | 99.67% | L5 | Genetic albumin defect, unrelated to antibacterial mechanism | | 4 | Blood group incompatibility | 99.55% | L5 | Immunohematology issue, unrelated to DNA gyrase inhibition | | 5 | Punctate epithelial keratoconjunctivitis | 99.54% | L4 | Cited literature is microsporidial (parasitic), not bacterial — likely TxGNN false positive | | 6 | Premalignant hematological system disease | 99.48% | L5 | No mechanistic link, no evidence | | 7 | Diffuse scleroderma | 99.44% | L5 | Autoimmune fibrotic disease, unrelated to antibacterial mechanism | | 8 | Monoclonal gammopathy | 99.42% | L5 | Cited literature is about fluoroquinolone resistance in cancer patients, not treatment of the condition | | 9 | Hematological disease with acquired peripheral neuropathy | 99.38% | L5 | No mechanistic link, no evidence |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.